Clinical and Experimental Hepatology
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2025
vol. 11
 
Share:
Send email
Share:
abstract:
Review paper

Recommendations for hypolipidemic and antithrombotic therapy in HCV-infected patients treated with direct-acting antiviral agents: expert position statement

Jerzy Jaroszewicz
1
,
Marlena Broncel
2
,
Anna Piekarska
3
,
Filip M. Szymanski
4
,
Krzysztof Tomasiewicz
5
,
Paweł Rajewski
6
,
Maciej Banach
7, 8
,
Bartosz Hudzik
9, 10
,
Mariusz Gąsior
9
,
Robert Flisiak
11
,
Robert Gil
12

  1. Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, Poland
  2. Department of Internal Medicine and Clinical Pharmacology, Medical University of Lodz, Centre for the Treatment of Lipid Disorders, Łódź, Poland
  3. Department of Infectious Diseases and Hepatology, Medical University of Lodz, Łódź, Poland
  4. Department of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland
  5. Department of Infectious Diseases and Hepatology, USK-1, Medical University of Lublin, Lublin, Poland
  6. Department of Internal and Infectious Diseases, Provincial Infectious Disease Hospital, Bydgoszcz, Poland
  7. Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland
  8. Faculty of Medicine, John Paul II Catholic University of Lublin, Lublin, Poland
  9. 3rd Department and Clinical Department of Cardiology, Faculty of Medicine with Division of Medicine and Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland
  10. Department of Cardiovascular Prevention, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, Poland
  11. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland
  12. National Medical Institute of the Internal Affairs and Administration Ministry, Warsaw, Poland
Clin Exp HEPATOL 2025; 11, 3: 205–218
DOI: https://doi.org/10.5114/ceh.2025.154978
Online publish date: 2025/09/30
View full text Get citation
 
PlumX metrics:
The recently observed increase in cardiovascular disease incidence in patients with chronic hepatitis C has contributed to hepatitis C virus (HCV) being considered a new, non-classical risk factor. HCV infection may also lead to the development of metabolic disorders, which play an important role in the development of cardiovascular diseases. The notable impact of HCV on the development of obesity, insulin resistance, diabetes, lipid disorders and fatty liver has led to metabolic disorders in the course of HCV infection being referred to as metabolic-viral syndrome. On the other hand, modern treatment of HCV infection with direct-acting antiviral drugs is extremely effective and safe, while drug interactions are the main potential limitation. This article presents expert recommendations for the diagnosis and treatment of heart disease and lipid disorders in HCV-infected patients.
keywords:

anticoagulants, HCV infection, lipid-lowering drugs, direct-acting antivirals, cardiovascular diseases
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.